U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216586) titled 'Zynrelef Versus Adductor Canal Block' on Oct. 10.
Brief Summary: To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Knee Osteoarthritis
Arthritis Knee
Intervention:
DRUG: ZYNRELEF 400Mg-12Mg Extended-Release Solution
A single 14 mL dose of HTX-011 containing 400 mg bupivacaine and 12 mg meloxicam will be applied intraoperatively to the surgical site. This FDA-approved formulation is designed to provide sustained analgesia for up to 72 hours ...